Clinical Report: Utilizing Machine Learning in Clinical Decision Support Systems

Overview

This scoping review explores the integration of machine learning (ML) in clinical decision support systems (CDSS) for predicting cancer treatment outcomes. It highlights the current landscape and challenges of ML applications in oncology.

Background

Cancer remains a leading cause of mortality, with significant variability in treatment responses and outcomes. Traditional decision-making frameworks often fall short in providing personalized treatment strategies. The integration of machine learning into CDSS offers a potential avenue for improving patient care in oncology.

Data Highlights

No specific numerical data provided in the source material.

Key Findings

• Machine learning algorithms can recognize complex patterns and stratify risk in oncology.
• ML-enabled CDSS can forecast treatment efficacy and identify adverse event risks.
• Real-world implementation of ML in oncology faces barriers such as interoperability and model interpretability.
• Existing literature lacks comprehensive synthesis on ML applications across diverse cancer types.
• Ethical and infrastructural considerations are critical for the integration of ML in clinical workflows.

Clinical Implications

Standardized protocols and validation strategies for ML models in oncology are necessary. Barriers to implementation must be addressed for effective integration.

Conclusion

The review highlights the challenges that must be addressed for effective implementation of machine learning in clinical decision support for oncology.

Related Resources & Content

1. Frontiers in Digital Health, 2026 -- Machine learning for chemotherapy decision-making in breast cancer using large language model
2. Journal of Medical Internet Research (JMIR), 2026 -- AI in Clinical Decision Support Systems: Promising Applications and Strategies for Managing Data Challenges
3. Emergency Medicine Journal, 2026 -- Clinician interaction with a machine learning algorithm for the assessment of patients with possible acute heart failure: a qualitative study
4. The ASCO Post, 2026 -- Machine-Learning Model for HCC Risk Prediction May Outperform Current Methods
5. FDA -- Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions
6. ASCO -- Policy Issues & Statements
7. PLOS Digital Health, 2026 -- Performance of predictive AI-based clinical decision support systems across clinical domains: A systematic review and meta-analysis
8. Nature Medicine, 2026 -- Generalizable AI predicts immunotherapy outcomes across cancers and treatments
9. Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions | FDA
10. Policy Issues & Statements - ASCO
11. Performance of predictive AI-based clinical decision support systems across clinical domains: A systematic review and meta-analysis | PLOS Digital Health
12. Generalizable AI predicts immunotherapy outcomes across cancers and treatments | Nature Medicine